Amyloid PET Imaging for Alzheimer's Disease Diagnosis

How do amyloid PET and CSF biomarker tests influence eligibility for FDA‑approved Alzheimer’s therapies?

‑approved anti‑amyloid therapies for early symptomatic Alzheimer’s disease require evidence of brain amyloid pathology before initiation, and clinicians most commonly rely on amyloid PET imaging or ce...